Human Genome Shares Rise On Lupus Drug Study Data
NEW YORK (AP) Shares of Human Genome Sciences Inc. jumped Thursday after the company said its drug candidate Benlysta reduced lupus symptoms over a four-year period in a study.
The stock jumped 59 cents, or 21.7 percent, to $3.30 in afternoon trading. Shares have traded between 45 cents and $8 over the last 52 weeks. The extended clinical trial showed that Benlysta patients experienced less severe flare-ups from the inflammatory disease and overall, those flare-ups decreased. The long-term study results come ahead of expected late-stage clinical trial data in July. Results from a second late-stage study are expected in November. "This (study) data makes us incrementally more positive on the upcoming pivotal Phase III BLISS-52 (study) data expected next month," wrote Leerink Swann Research analyst Joseph P. Schwartz in a note to investors. He maintained an "Outperform" rating on the stock. Benlysta was previously called LymphoStat-B, and is being developed through a partnership between Rockville, Md.-based Human Genome Sciences and British drug maker GlaxoSmithKline PLC.- Loading Comments...
- Loading Comments...
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,023.42 | 1,069.30 | 2,112.44 | 35.03 |
Oil *
76.05
|
|
UP
17.46
|
UP
2.67
|
UP
7.12
|
DOWN
0.30
|
10 Yr
3.50%
SPDR Gold
107.43
|
|
+0.17%
|
+0.25%
|
+0.34%
|
-0.85%
|
Data delayed 20 minutes |














